Mucosal Protection Leyden Labs is actively developing a Mucosal Protection Platform with intranasal products targeting broad protection against respiratory viruses, presenting opportunities to partner with vaccine developers, pharma distributors, and healthcare providers focused on respiratory disease prevention and outbreak mitigation.

Strategic Partnerships Recent and ongoing collaborations with the International Vaccine Institute and related infectious disease prevention initiatives suggest open avenues for co-development, joint ventures, and regional deployment programs in Asia and Europe.

Clinical Pipeline Lead program PanFlu and acquired assets like RIGImmune’s RIG-101 indicate an expanded intranasal antibody pipeline, creating sales opportunities with pharma researchers, contract development and manufacturing organizations, and clinical trial networks.

Emerging Leadership Experienced leadership and recent CTO appointment together with notable industry accolades position Leyden Labs as a credible partner; leverage this for value demonstrations, advisory collaborations, and large-scale project sponsorships.

Global Expansion Digital and data-enabled operations (Power BI, Tableau, Smartsheet, OpenAI) alongside a Netherlands base and international partnerships point to opportunities in regional market access, distribution partnerships, and technology-enabled program management services.